The coagulation enzyme factor Xa (FXa) has been recognized as a promising target for the
development of new antithrombotic agents. We previously found compound 1 to be an orally …

Factor Xa, a critical serine protease in the blood coagulation cascade, has become a target
for inhibition as a strategy for the invention of novel anti-thrombotic agents. Here we …

Ischemic heart disease and cerebrovascular disease are the leading causes of death in the
world. Surprisingly, these diseases are treated by relatively antiquated drugs. However, due …

Factor Xa (FXa), a vitamin K-dependent serine protease plays a pivotal role in the
coagulation cascade, one of the most interesting targets for the development of new …

Based on DuPont Pharmaceuticals' monobenzamidine lead structure SN429, we have
designed the biphenyl 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as a novel series of …

Structure and property based drug design was exploited in the synthesis of
sulfonamidopyrrolidin-2-one-based factor Xa (fXa) inhibitors, incorporating biaryl P4 groups …

A novel series of triaryloxypyridines have been designed to inhibit factor Xa, a serine
protease strategically located in the coagulation cascade. Inhibitor 5e has a KI against factor …

New chloro-substituted biarylmethoxyphenyl piperidine-4-carboxamides were synthesized
and assayed in vitro as inhibitors of the blood coagulation enzymes factor Xa (fXa) and …

The serine protease factor Xa is a critical enzyme in the blood coagulation cascade.
Recently, the inhibition of factor Xa has begun to emerge as an attractive strategy for the …

Sulfonamidopyrrolidinones were previously disclosed as a selective class of factor Xa (fXa)
inhibitors, culminating in the identification of RPR120844 as a potent member with efficacy …